Quantcast
Last updated on April 17, 2014 at 8:56 EDT

Latest Celtaxsys Inc. Stories

2013-10-10 16:27:01

ATLANTA, Oct. 10, 2013 /PRNewswire/ -- Pharmaceutical discovery and development company Celtaxsys, Inc. today announced it is now enrolling patients for its first trial of CTX-4430 oral treatment for lung disease in Cystic Fibrosis (CF) patients. In this study, the safety and tolerability of CTX-4430 will be assessed at several dose levels when administered orally once-daily for 2 weeks. Additional assessments will include pharmacokinetics and biomarkers, as well as effects on lung...

2013-09-16 16:25:21

ATLANTA, Sept. 16, 2013 /PRNewswire/ -- Atlanta-based pharmaceutical discovery and development company, Celtaxsys, Inc., announced today the achievement of a significant clinical milestone for its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis (CF) lung disease. Celtaxsys has successfully completed the first of two clinical trials in its Phase 1 program, and the first trial conducted through its Australia subsidiary, Celtaxsys Aus Pty Ltd. In this...

2013-09-09 16:24:20

ATLANTA, Sept. 9, 2013 /PRNewswire/ -- Celtaxsys, Inc., an Atlanta-based pharmaceutical discovery and development company, announced today that it has restructured its management and operations to focus on development of its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis (CF) lung disease. As part of the restructuring, Dr. Michael Hanley has retired from his role as CEO and Chairman, and Dr. Brett Premack has stepped down as CTO. Dr. H. Daniel Perez,...

2012-10-23 11:25:51

SAN FRANCISCO, Oct. 23, 2012 /PRNewswire/ -- Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat inflammatory disorders through innate immunity, today announced the appointment of life sciences technology expert, Brett A. Premack, Ph.D., as Chief Technology Officer. "Dr. Brett Premack has a wealth of drug development expertise and high level strategic leadership in bringing successful new anti-inflammatory products to the clinic, which is an ideal...

2012-01-05 14:00:00

SAN FRANCISCO, Jan. 5, 2012 /PRNewswire/ -- Celtaxsys, Inc. a privately held biotechnology company, announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc. In preclinical studies, CTX-4430 has demonstrated the ability to safely and effectively reduce the progression of chronic inflammation in several animal models. LTA4H is a...

2011-06-06 13:47:00

SAN FRANCISCO, June 6, 2011 /PRNewswire/ -- Celtaxsys, Inc., a private biopharmaceutical company defining new therapeutics in inflammation, announces the appointment of life sciences industry veteran, H. Daniel Perez, M.D., to its Board of Directors (BOD). "We are delighted that Dr. Perez has joined the Celtaxsys team," says Dr. Michael R. Hanley, CEO and Chairman of the Board of Celtaxsys. "He brings more than 25 years of high level pharmaceutical executive experience to the BOD, in...

2010-12-02 13:49:00

ATLANTA, Dec. 2, 2010 /PRNewswire/ -- Georgia -based drug discovery start-up, Celtaxsys, Inc. is pleased to announce that Dr. Michael Hanley has joined the company as its new Chief Executive Officer and Chairman of the Board of Directors. Dr. Hanley has served on both the Scientific Advisory Board and Board of Directors of Celtaxsys since 2007. Dr. Hanley brings more than 20 years of managerial experience in the international life science industry including drug discovery, product...